← Leaderboards
Xiaodong Cheng
University Of Texas Medical Br Galveston
$12,206,661
Attributed
$17,765,782
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,765,782 · 9
By mechanism
R01$15,543,403 · 5
R35$1,876,599 · 1
R21$191,250 · 1
R56$150,000 · 1
R03$4,530 · 1
Top collaborators
- Hua Liu5 shared
- David H Walker5 shared
- Oleh Pochynyuk3 shared
- Jia Zhou3 shared
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- David H Walker$27,320,724
Others in their field
Top investigators on “Cyclic Amp”
- Susan S Taylor · University Of California, San Diego$26,467,193
- David Heimbrook · Leidos Biomedical Research, Inc.$26,054,235
- Amy F.t. Arnsten · Yale University$18,857,746
- Andrew R Marks · Columbia University Health Sciences$17,939,974
- Jin Zhang · University Of California, San Diego$17,177,896
- Dennis Brown · Massachusetts General Hospital$16,250,225
Research focus
Cyclic AmpSignal TransductionProteinsMediatingCyclic Amp-Dependent Protein KinasesPhysiologicalSecond Messenger SystemsMolecularGuanine Nucleotide Exchange FactorsPlayTherapeutic TargetCyclic Amp ReceptorsIn VivoBaseLaboratoriesBiological ProcessDiabetes MellitusLeadAnimal ModelCollaborationsKnockout MiceMalignant NeoplasmsEukaryotic CellHeart Failure
Grant awards (40)
Significance of Epac signaling in renal Na+handling and hypertension$678,566
R01 · FY2025 · DK
Epac1 as a novel therapeutic target for diabetic retinopathy$506,223
R01 · FY2025 · EY · contact PI
Epac1 as a novel therapeutic target for diabetic retinopathy$40,487
R01 · FY2025 · EY · contact PI
Significance of Epac signaling in renal Na+handling and hypertension$678,566
R01 · FY2024 · DK
Epac1 as a novel therapeutic target for diabetic retinopathy$506,223
R01 · FY2024 · EY · contact PI
Epac1 as a novel therapeutic target for diabetic retinopathy$506,223
R01 · FY2023 · EY · contact PI
Significance of Epac signaling in renal Na+ handling and hypertension$150,000
R56 · FY2023 · DK
Epac1 as a novel therapeutic target for diabetic retinopathy$514,763
R01 · FY2022 · EY · contact PI
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics$428,510
R35 · FY2021 · GM · contact PI
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics$428,510
R35 · FY2020 · GM · contact PI
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics$47,999
R35 · FY2020 · GM · contact PI
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics$428,510
R35 · FY2019 · GM · contact PI
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1$1,200,531
R01 · FY2018 · AI · contact PI
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics$428,510
R35 · FY2018 · GM · contact PI
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1$1,209,563
R01 · FY2017 · AI · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$372,647
R01 · FY2017 · GM · contact PI
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics$114,560
R35 · FY2017 · GM · contact PI
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1$1,256,218
R01 · FY2016 · AI · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$372,647
R01 · FY2016 · GM · contact PI
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1$1,255,285
R01 · FY2015 · AI · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$372,647
R01 · FY2015 · GM · contact PI
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)$308,233
R01 · FY2015 · GM · contact PI
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1$1,538,676
R01 · FY2014 · AI · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$395,709
R01 · FY2014 · GM · contact PI
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)$277,625
R01 · FY2014 · GM · contact PI
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)$491,061
R01 · FY2013 · GM · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$234,215
R01 · FY2013 · GM · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$95,634
R01 · FY2013 · GM · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$344,608
R01 · FY2012 · GM · contact PI
High throughput assay for novel pharmacological probes targeting cAMP signaling$38,250
R21 · FY2012 · NS · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$343,928
R01 · FY2011 · GM · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$349,680
R01 · FY2010 · GM · contact PI
High throughput assay for novel pharmacological probes targeting cAMP signaling$153,000
R21 · FY2010 · NS · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$357,970
R01 · FY2009 · GM · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$257,128
R01 · FY2007 · GM · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$264,807
R01 · FY2006 · GM · contact PI
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$271,180
R01 · FY2005 · GM
Genetic Screening:Oncogene RAS-Based Inhibi*(RMI)$4,530
R03 · FY2005 · MH
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$271,180
R01 · FY2004 · GM
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor$271,180
R01 · FY2003 · GM